AE Wealth Management LLC Has $43.90 Million Holdings in Amgen Inc. $AMGN

Key Points

• AE Wealth Management increased its Amgen stake by 21.7% in Q4 to 134,132 shares, valued at about $43.90 million.
• Amgen beat Q4 estimates, reporting $5.29 EPS (vs. $4.76 expected) and $9.87 billion revenue (vs. $9.46 billion), and set FY2026 EPS guidance of 21.60–23.00.
• Amgen declared a quarterly dividend of $2.52 (annualized $10.08, ~2.9% yield) with an ex-dividend/record date of May 15 and a payment date of June 5.

AE Wealth Management LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 21.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 134,132 shares of the medical research company's stock after buying an additional 23,909 shares during the period. AE Wealth Management LLC's holdings in Amgen were worth $43,903,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in AMGN. Board of the Pension Protection Fund bought a new position in shares of Amgen in the fourth quarter worth $26,000. Olistico Wealth LLC acquired a new position in shares of Amgen in the 4th quarter valued at approximately $33,000. Cloud Capital Management LLC acquired a new position in shares of Amgen in the 3rd quarter valued at approximately $34,000. Saranac Partners Ltd bought a new stake in shares of Amgen during the 3rd quarter worth approximately $37,000. Finally, Holos Integrated Wealth LLC bought a new stake in shares of Amgen during the 4th quarter worth approximately $37,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $349.39 on Friday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The firm has a market cap of $188.56 billion, a PE ratio of 24.55, a price-to-earnings-growth ratio of 3.28 and a beta of 0.47. The firm's fifty day moving average is $363.49 and its 200-day moving average is $336.75.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen's revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period last year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen's payout ratio is presently 70.84%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on AMGN. Wall Street Zen raised shares of Amgen from a "hold" rating to a "buy" rating in a research note on Saturday, April 11th. The Goldman Sachs Group raised their target price on Amgen from $403.00 to $415.00 and gave the company a "buy" rating in a report on Wednesday, February 4th. Guggenheim lifted their price target on Amgen from $347.00 to $351.00 and gave the company a "neutral" rating in a research note on Thursday, April 9th. Mizuho boosted their price target on Amgen from $280.00 to $295.00 and gave the stock an "outperform" rating in a report on Tuesday, February 10th. Finally, Piper Sandler upped their price objective on Amgen from $381.00 to $432.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Amgen currently has a consensus rating of "Hold" and a consensus price target of $356.24.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.